(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives
AstraZeneca Secures $555 Million Deal for Gene-Editing Technology
AstraZeneca's Strategic Partnership with Algen
(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
Details of the Agreement
The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.
Implications for Gene-Editing Therapies
Reuters could not immediately confirm the FT report.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)


